Duke Receives $69 Million NIH Grant to Translate Science into Better Health for All
On Aug. 29, 2025, the National Institutes of Health (NIH) announced it had awarded Duke University $69 million…
-
-
C2N Diagnostics Expands the PrecivityAD2™ Alzheimer’s Disease Blood Test Intended Use to Patients 50 Years and Older
On Aug. 25, 2025, C2N Diagnostics (C2N) announced lower age limit addresses increasing calls from clinicians seeking access…
-
CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation
On Aug. 6, 2025, CareDx announced the publication of the Kidney Allograft Outcomes AlloSure Registry (KOAR) study in…
-
C2N Diagnostics Expands Portfolio of Blood Tests for Clinical Researchers Studying Alzheimer’s Disease and Related Dementias
On Jul. 15, 2025, C2N Diagnostics (C2N), announces the launch of two new highly anticipated plasma assays for…
-
Agriculture | Biotechnology | Clinical Research | Cloning | COVID-19 | Diagnostics | FDA | Genomics | Infectious Disease | Marine Science | Medical Device | NIH | Non-Profit Research | Oncology | Stem Cell | Therapeutics | U.S. Congress | USDA | Vaccine | Veterinary | Women's Health
NIH will reinstate 900 grants in response to court order
On Jun. 25, 2025, the National Institutes of Health (NIH) moved to reinstate about 900 grants that a…
-
New therapeutic strategy help lower cholesterol levels by 50%
On Jun. 11, 2025, a study led by by University of Barcelona experts Carles J. Ciudad and Verònica…
-
Accuracy of diagnostic blood tests for Alzheimer’s disease varies
On Jul. 30, 2024, a head-to-head comparison of six commercially available blood tests for Alzheimer’s disease led by…
-
C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories
On Jun. 27, 2024, C2N Diagnostics (C2N), has entered into a non-exclusive agreement with Mayo Clinic Laboratories, for…
-
C2N Diagnostics’ PrecivityAD2™ Blood Test Receives MHRA Medical Device Certification in the United Kingdom
On Feb. 24, 2024, C2N Diagnostics (C2N) announced the medical device registration from the United Kingdom’s Medicines and…
-
Biotechnology | Clinical Research | Disease | Medicine | Neurology | Oncology | Stem Cell | Therapeutics
California’s Stem Cell Agency awarded $56 million for clinical research, $21.3 million for Shared Labs program
On Feb. 23, 2024, the California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative…
-
Biotechnology | Clinical Research | COVID-19 | FDA | Infectious Disease | Medicine | NIH | Therapeutics | Vaccine
FDA issued final guidance on developing drugs for COVID-19 treatment and preventionﾠ
On Nov. 22, 2023, the U.S. Food and Drug Administration (FDA) issued the final guidance COVID-19: Developing Drugs…
-
Large-scale genetic analysis showed microRNAs in human pancreas associated with diabetes
On Feb. 9, 2023, the National Institutes of Health (NIH) announced that a new large-scale genetic analysis found…
-
Biotechnology | Clinical Research | COVID-19 | Diagnostics | Infectious Disease | NIH | Non-Profit Research | Therapeutics | Vaccine
Hutchinson Cancer Center leads large-scale review of COVID-19 clinical trials that highlights multiple disparities
On Dec. 5, 2022, the Fred Hutchinson Cancer Center announced that according to a new meta-analysis women were…
-
Biotechnology | Clinical Research | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine
Moderna’s BA.4/BA.5 targeting bivalent booster, mRNA-1273.222, met primary endpoint
On Nov. 15, 2022, Moderna reported findings from a Phase II/III clinical trial where bivalent Omicron-targeting booster candidates,…
-
Innovation Pharmaceuticals reported additional findings from Brilacidin phase 2 COVID-19 tial results
On Mar. 7, 2022, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
-
Innovation Pharmaceuticals conducted full data analysis of phase 2 brilacidin COVID-19 trial results to support inclusion in Government-sponsored trials
On Nov. 12, 2021, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
-
Senolytics reduced COVID-19 symptoms in preclinical studies
On Jun. 8, 2021, Mayo Clinic researchers and colleagues at the University of Minnesota showed that COVID-19 exacerbates…
-
Moderna announced primary efficacy analysis in phase 3 COVE study for COVID-19 vaccine candidate
On Nov. 30, 2020, Moderna announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273…
-
Gilead announced long-acting HIV-1 capsid inhibitor, lenacapavir, achieved primary endpoint in phase 2/3 study
On Nov. 18, 2020, Gilead Sciences announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s…
-
NIH funded first nationwide network to study rare forms of diabetes
On Sept. 30, 2020, the National Institutes of Health (NIH) announced funding of a nationwide study to discover…
-
Members of the COVID R&D alliance and quantum leap healthcare collaborative enrolled first patients in I-SPY COVID trial
On Aug. 3, 2020, members of the COVID R&D Alliance AbbVie, Amgen and Takeda Pharma announced the first…
-
Atossa Therapeutics received approval to open clinical study of AT-301 nasal spray being developed to treat COVID-19
On Aug. 3, 2020, Atossa Therapeutics announced that it had received approval from the ethics committee to open…
-
AIM ImmunoTech announced NCI award of $14.54 million to study Ampligen as part of five Roswell Park-led chemokine modulation clinical trials in melanoma, colorectal and ovarian cancers
On Apr. 6, 2020, the National Cancer Institute awarded of $14.54 million to Roswell Park Comprehensive Cancer Center…
-
Moderna shipped mRNA vaccine against novel Coronavirus (mRNA-1273) for phase 1 study
On Feb. 24, 2020, Moderna announced it had released the first batch of mRNA-1273, the Company’s vaccine against…
-
FDA approved new sickle cell treatment based on clincal trial results from UTHSC’s Kenneth Ataga, MD
On Dec. 2, 2019, the U.S. Food and Drug Administration (FDA) announced it had approved the drug crizanlizumab…
-
Canadian Cancer Trials Group announced IND.234 clinical trial using liquid biopsy technology for prostrate cancer screening
On Nov. 27, 2018, the Canadian Cancer Trials Group, a new clinical trial, opened across Canada. This was…
-
Scripps Health and MD Anderson Cancer Center announced partnership to create clinically integrated cancer program
On Aug. 29, 2016, Scripps Health and MD Anderson Cancer Center announced a partnership agreement to create Scripps…
-
Phase III results for first HIV/AIDS (Aidsvax) vaccine reported
On Sept. 24, 2009, the second Phase III HIV-1 vaccine trial, also known as RV144, that began in…
-
Clinical Research | Disease | FDA | IRB | Medicine | Oncology | Therapeutics | Women's Health
FDA issued guidelines calling for improved assessments of medication responses as a function of gender
On Jul. 22, 1993, revising a policy from 1977 that excluded women of childbearing potential from early drug…
-
Biotechnology | Clinical Research | Diagnostics | Oncology | Radiology | Therapeutics | Women's Health
The Prostate, Lung, Colorectal, and Ovarian trial began recruiting 148,000 men and women, ages 55-74
In 1993, the Prostate, Lung, Colorectal, and Ovarian trial was launched. The trial was designed to determine whether…
